NCT06947928
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06947928
Title Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naive Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TuHURA Biosciences, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
USC Norris Comprehensive Cancer Center RECRUITING Los Angeles California 90033 United States Details
Stanford Health Care - Skin Cancer Program RECRUITING Palo Alto California 94304 United States Details
University of California San Francisco - Helen Diller Family Comprehensive Cancer Center RECRUITING San Francisco California 94143 United States Details
Dana-Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Atlantic Health System RECRUITING Morristown New Jersey 07960 United States Details
East Carolina University RECRUITING Greenville North Carolina 27834 United States Details
Virginia Commonwealth University - Massey Cancer Center RECRUITING Richmond Virginia 23298 United States Details
Fred Hutchinson Cancer Research Center RECRUITING Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field